BioNTech to Join High-level Meeting with Partners in Marburg and to Hold Press Conference to Provide an Update on Sustainable Vaccine Manufacturing in Africa

Rhea-AI Summary

BioNTech SE (Nasdaq: BNTX) announced a high-level meeting in Marburg aimed at promoting sustainable vaccine manufacturing within the African Union. This initiative, led by the kENUP foundation, includes distinguished participants such as the President of Senegal and the Director General of the WHO. Public statements will occur on February 16, 2022, followed by a digital press conference detailing BioNTech's vaccine manufacturing efforts in Africa. This meeting underscores the company's commitment to expanding its vaccine production capabilities.

Positive

• Collaboration with the African Union to enhance vaccine manufacturing.
• High-level engagement with global leaders and WHO representatives.
• Commitment to expanding vaccine production capabilities in Africa.

Negative

• None.

MAINZ, Germany, February 15, 2022 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will welcome project partners, among them official representatives, in Marburg to conduct a high-level meeting on sustainable vaccine manufacturing in the African Union. The meeting initiated by the kENUP foundation will be followed by public statements on February 16, 2022 at approx. 11.30 CET / 05.30 ET from the following participants:

• H.E. President Macky Sall of Senegal, President of the African Union
• H.E. President Nana Akufo-Addo of Ghana
• H.E. President Paul Kagame of Rwanda
• Tedros Adhanom Ghebreyesus, Director General of the World Health Organization
• Ugur Sahin, Chief Executive Officer of BioNTech SE
• Sierk Poetting, Chief Operating Officer of BioNTech SE

The statements can be accessed via live-stream and broadcast usage here: Link

Following the public statements, BioNTech will hold a digital press conference to provide an update on its vaccine manufacturing efforts on the African continent.

International press conference at approx. 14.30 CET / 08.30 ET
BioNTech participants: Ugur Sahin, CEO and Co-founder; Sierk Poetting, COO

Interested journalists may dial in 10-15 minutes before the conference starts. They will be able to submit questions via an online tool. Please register here for participation: Link

Participants can also access the press conference, including the video webcast, on https://biontech.de/ under “Events & Presentations” in the Investor & Media section of the website. A recording of the press conference will be made available on the same day.

About BioNTech
Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer. For more information, please visit www.BioNTech.de.

Media Relations
Jasmina Alatovic
+49 (0)6131 9084 1513
Media@biontech.de  

Investor Relations
Sylke Maas, Ph.D.
+49 (0)6131 9084 1074
Investors@biontech.de

FAQ

What is BioNTech announcing on February 15, 2022?

BioNTech is announcing a high-level meeting focused on sustainable vaccine manufacturing in the African Union.

Who are the key participants in BioNTech's meeting?

Participants include leaders from Senegal, Ghana, Rwanda, the WHO Director General, and BioNTech executives.

What is the date of the public statements from the meeting?

The public statements will take place on February 16, 2022.

How can I access BioNTech's press conference regarding vaccine manufacturing in Africa?

The press conference can be accessed through a live stream on BioNTech's website.

What is the significance of BioNTech's meeting with the African Union?

The meeting aims to promote sustainable vaccine manufacturing in Africa, highlighting BioNTech's commitment to global health.